OMN-54(OMN-54) - 药物靶点：Adenosine receptor x COX-2 x PXR_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Aneustat、OMN 54、OMN54

靶点

Adenosine receptor x COX-2 x PXR

作用方式

激动剂、抑制剂

作用机制

腺苷受体家族激动剂、COX-2抑制剂(环氧化酶-2抑制剂)、PXR激动剂(孕烷X受体激动剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病

在研适应症-

非在研适应症

晚期癌症淋巴瘤实体瘤

原研机构

Genyous Biomed International, Inc.

在研机构-

非在研机构

Genyous Biomed International, Inc.

Omnitura Therapeutics, Inc.

权益机构-

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 OMN-54 相关的临床试验

NCT03495479

/ WithdrawnN/A

Phase IIA, Single-Center, Single-Arm Clinical Study of OMN54 (Aneustat) in Men Diagnosed With Prostate Cancer Being Followed by Active Surveillance

Assessment of the effects of OMN54 (Aneustat) in a population of men with indolent prostate cancer who are otherwise healthy and free of significant co-morbidities and have chosen active surveillance for disease management. The investigators will assess how OMN54 affects PSA, overall tumor burden in addition to any changes in urinary flow. Other biomarkers will be tested to follow disease evolution.

开始日期2025-01-01

申办/合作机构

Omnitura Therapeutics, Inc.

[+1]

NCT01555242

/ Completed临床1期

A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Aneustat™ (OMN54) Administered on a Daily Oral Regimen in Patients With Advanced Cancer and Lymphomas

This is a phase I, open-label, multiple dose, dose escalation study to assess the safety, tolerability and pharmacokinetics of Aneustat™ (OMN54), a novel therapy, administered orally in patients with advanced cancer and lymphomas.

开始日期2012-08-01

申办/合作机构

Omnitura Therapeutics, Inc.

100 项与 OMN-54 相关的临床结果

登录后查看更多信息

100 项与 OMN-54 相关的转化医学

登录后查看更多信息

100 项与 OMN-54 相关的专利（医药）

登录后查看更多信息

1

项与 OMN-54 相关的文献（医药）

2009-12-01·Chinese medicine3区 · 医学

A novel combination of Chinese medicines to treat advanced cancers and lymphomas in rats

3区 · 医学

ArticleOA

作者: Waterhouse, Dawn N

Chinese medicine often targets more than one system and as such comprises several compounds, often in non-purified form, with treatments therefore consisting of whole extracts of herbs rather than isolated compounds. The additive and synergistic effects of the phytochemicals in OMN54, a novel mixture of extracts from three commonly used Chinese medicine components; Ganoderma lucidum, Salvia miltiorrhiza and Scutellaria barbata, were previously demonstrated to have potent anti-cancer activity. This study aims to test whether this heterogeneous, multifunctional and multitargeted agent has an acceptable toxicity profile.

100 项与 OMN-54 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期癌症	临床1期	加拿大	Omnitura Therapeutics, Inc.	2012-08-01
淋巴瘤	临床1期	加拿大	Omnitura Therapeutics, Inc.	2012-08-01
实体瘤	临床1期	加拿大	Genyous Biomed International, Inc.	-